Jacobi Capital Management’s Traws Pharma TRAW Stock Holding History

Jacobi Capital Management’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-213	Closed	-$22K	–	1383
2020 Q3	$22K	Buy	+213	New	+$52.6K	﹤0.01%	656

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HWA

Hillcrest Wealth Advisors Hazlet, New Jersey $279M AUM 21.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jacobi Capital Management's TRAW Position: Q4 2020 in Review

Jacobi Capital Management sold out of Traws Pharma (TRAW) in Q4 2020, closing a stake of 213 shares — an estimated $22K sold.

Jacobi Capital Management first reported a position in TRAW in Q3 2020 and held it in 1 quarter. The position peaked at $22K in Q3 2020. 33 funds tracked by Wall St. Rank hold TRAW as of Q4 2020.

Jacobi Capital Management reported no remaining Traws Pharma position as of Q4 2020 after selling out during the quarter.
Jacobi Capital Management sold 213 Traws Pharma shares in Q4 2020, an estimated $22K.
Jacobi Capital Management first reported a position in Traws Pharma in Q3 2020 and held it in 1 quarter.
Jacobi Capital Management's Traws Pharma position peaked at $22K in Q3 2020.
33 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2020.

Based on Jacobi Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.